XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER EXPENSE, NET
 12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
OTHER EXPENSE, NET OTHER EXPENSE, NET
Other expense, net for the years 2023, 2022 and 2021 consists of:
(in millions)202320222021
Litigation and other matters$(53)$9 $356 
Acquired in-process research and development costs— 1 8 
Net gain on sale of assets(3)(5)(2)
Acquisition-related contingent consideration59 29 11 
Acquisition-related transaction costs24 — — 
Other, net1 1 — 
Other expense, net$28 $35 $373 
In 2023, Litigation and other matters primarily related to insurance recoveries regarding certain litigation matters, Acquisition-related contingent consideration reflects adjustments for changes in estimates in the timing and amounts of the future royalty and milestone payments related to certain branded products and Acquisition-related transaction costs primarily related to transaction costs attributable to the acquisition of XIIDRA® by Bausch + Lomb.
In 2021, Litigation and other matters of $356 million included adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters and Net gain on sales of assets included $25 million related to the achievement of a milestone related to a certain product and a $26 million loss upon completion of the Amoun Sale.